Voices
Jad Chahoud: Rethinking the “Undruggable” TP53 Through Early Clinical Innovation
Jad Chahoud/LinkedIn

Jad Chahoud: Rethinking the “Undruggable” TP53 Through Early Clinical Innovation

Jad Chahoud, Chief Scientific and Innovation Officer at Orlando Health Cancer Institute, shared a post on LinkedIn:

“TP53 is considered the ultimate “undruggable” target. This new NEJM Group phase 1 trial suggests that may be changing:

  • 77 heavily pretreated pts with TP53 Y220C mutant solid tumors
  • First-in-class oral p53 reactivator (rezatapopt)
  • 20% ORR overall
  • 30% ORR in KRAS wild-type at active doses
  • Responses across ovarian, breast & other tumors
  • Mostly grade 1–2 AEs; only 3% discontinued.”

Title: Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Authors: Ecaterina E. Dumbrava, Geoffrey I. Shapiro, Aparna R. Parikh, Melissa L. Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, Andrae L. Vandross, Shivaani Kummar, Dale R. Shepard, Kim LeDuke, Lisa Sheehan, Leila Alland, Arshad Haque, Deepika Jalota, Marc Fellous, Alison M. Schram

Read the Full Article.

Other articles featuring Jad Chahoud on OncoDaily.

 

Alison M. Schram Andrae L. Vandross Anthony B. El-Khoueiry Anthony W. Tolcher Aparna R. Parikh Arshad Haque cancer Dale R. Shepard Deepika Jalota Ecaterina E. Dumbrava Geoffrey I Shapiro Jad Chahoud John A. Thompson Kim LeDuke Leila Alland Lisa Sheehan Marc Fellous Melissa L. Johnson OncoDaily Oncology Shivaani Kummar